The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Welcome to The Non-Hodgkin Lymphoma (NHL) Channel
VJHemOnc shares with you the most impactful updates and insights in the field of non-Hodgkin lymphoma (NHL), directly from top researchers from around the world. As well as video interviews on key talks and abstracts from major international congresses, you can explore our ever-growing selection of podcasts, roundtable discussions and more to stay up-to-date on critical updates in the NHL field.
The Non-Hodgkin Lymphoma Channel brings you updates from key clinical trials of CAR-T & cellular therapies, immunotherapies and novel combination regimens for the treatment of NHL. Findings from studies of real-world data and research identifying novel biomarkers are presented, in addition to commentary on the impact of novel therapies and considerations for integration into routine clinical practice.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
Diamond Supporter
Gold Supporter
Silver Supporter
Bronze Supporter
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.
